Nicholas Galakatos Ph.D

Nicholas Galakatos Ph.D General Information

Biography

Dr. Nicholas Galakatos serves as Global Head of BXLS and Senior Managing Director at Blackstone Life Sciences. He serves as an Global Head of Life Sciences & Chairman of Investment Committee of Blackstone. He serves as Chairman at Anthos Therapeutics. He serves as a Board Member at Neurvati Neurosciences. He served as a Board Member at Nuvelution Pharma. He is an Independent Director of Portola Pharmaceuticals, Inc. He has served as a member of our board of directors and as a member of our nominating and corporate governance committee since November 2003. He has also been a General Partner of MPM BioVentures II GP, LP and BioVentures III GP, LP, both venture funds, since April 2000 and December 2002, respectively. From 1997 to 2000, he served as Vice President, of New Business, and a member of the management team at Millennium. He was a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he also was the Chairman and founding Chief Executive Officer. He has served as the lead director at Affymax Inc. and a director of Cornerstone Therapeutics, Inc. (formerly Critical Therapeutics Inc.) and Aveo Pharmaceuticals, Inc. He holds a B.A. in Chemistry from Reed College and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and performed postdoctoral studies in molecular biology at Harvard Medical School.